{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:05:13Z","timestamp":1784275513528,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-026-06218-w","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:15:30Z","timestamp":1783336530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["VEXAS syndrome unmasked from relapsing polychondritis and infection mimicry: a case-based review"],"prefix":"10.1007","volume":"46","author":[{"given":"Zhongli","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1434-3568","authenticated-orcid":false,"given":"Fuxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2015-7473","authenticated-orcid":false,"given":"Wanrong","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"6218_CR1","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA et al (2020) Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 383:2628\u20132638. https:\/\/doi.org\/10.1056\/NEJMoa2026834","journal-title":"N Engl J Med"},{"key":"6218_CR2","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/art.42258","volume":"74","author":"PC Grayson","year":"2022","unstructured":"Grayson PC, Beck DB, Ferrada MA et al (2022) VEXAS syndrome and disease taxonomy in rheumatology. Arthritis Rheumatol 74:1733\u20131736. https:\/\/doi.org\/10.1002\/art.42258","journal-title":"Arthritis Rheumatol"},{"key":"6218_CR3","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1182\/blood.2022016985","volume":"140","author":"MA Ferrada","year":"2022","unstructured":"Ferrada MA, Savic S, Cardona DO et al (2022) Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood 140:1496\u20131506. https:\/\/doi.org\/10.1182\/blood.2022016985","journal-title":"Blood"},{"key":"6218_CR4","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","volume":"5","author":"IE Obiorah","year":"2021","unstructured":"Obiorah IE, Patel BA, Groarke EM et al (2021) Benign and malignant haematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv 5:3203\u20133215. https:\/\/doi.org\/10.1182\/bloodadvances.2021004976","journal-title":"Blood Adv"},{"key":"6218_CR5","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1038\/s41375-025-02775-4","volume":"39","author":"M Sakuma","year":"2025","unstructured":"Sakuma M, Wang AK, Magaziner SJ et al (2025) Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations. Leukemia 39:2872\u20132880. https:\/\/doi.org\/10.1038\/s41375-025-02775-4","journal-title":"Leukemia"},{"key":"6218_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(25)02164-6","volume":"407","author":"EM Groarke","year":"2026","unstructured":"Groarke EM, Turturice B, Patel BA et al (2026) VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies. Lancet 407:637\u2013648. https:\/\/doi.org\/10.1016\/S0140-6736(25)02164-6","journal-title":"Lancet"},{"key":"6218_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/art.43327","volume":"78","author":"M Anderson","year":"2026","unstructured":"Anderson M, Ercelen D, Richardson A et al (2026) Clinical manifestations of VEXAS syndrome across a broad spectrum of UBA1 mutation burden. Arthritis Rheumatol 78:223\u2013230. https:\/\/doi.org\/10.1002\/art.43327","journal-title":"Arthritis Rheumatol"},{"key":"6218_CR8","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.3346\/jkms.2024.39.e225","volume":"39","author":"IC Benlidayi","year":"2024","unstructured":"Benlidayi IC, Gupta L (2024) CAse-BAsed REview sTandards (CABARET): considerations for authors, reviewers, and editors. J Korean Med Sci 39:e225. https:\/\/doi.org\/10.3346\/jkms.2024.39.e225","journal-title":"J Korean Med Sci"},{"key":"6218_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s00296-026-06130-3","volume":"46","author":"N Giachetti","year":"2026","unstructured":"Giachetti N, Hadjadj J, Gaudr\u00e9 N et al (2026) Exploring glucocorticoid dose-response patterns in VEXAS syndrome: a pilot retrospective study. Rheumatol Int 46:88. https:\/\/doi.org\/10.1007\/s00296-026-06130-3","journal-title":"Rheumatol Int"},{"key":"6218_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00296-025-05824-4","volume":"45","author":"SJ Saur","year":"2025","unstructured":"Saur SJ, Obermaier B, Klein R et al (2025) Altered IgG4 serum levels in VEXAS syndrome\u2014a retrospective monocentric cohort study. Rheumatol Int 45:79. https:\/\/doi.org\/10.1007\/s00296-025-05824-4","journal-title":"Rheumatol Int"},{"key":"6218_CR11","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1136\/annrheumdis-2021-220876","volume":"80","author":"Y Kirino","year":"2021","unstructured":"Kirino Y, Takase-Minegishi K, Tsuchida N et al (2021) Tocilizumab in VEXAS relapsing polychondritis: a single-centre pilot study in Japan. Ann Rheum Dis 80:1501\u20131502. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220876","journal-title":"Ann Rheum Dis"},{"key":"6218_CR12","doi-asserted-by":"publisher","first-page":"e002255","DOI":"10.1136\/rmdopen-2022-002255","volume":"8","author":"M-Y Khitri","year":"2022","unstructured":"Khitri M-Y, Guedon AF, Georgin-Lavialle S et al (2022) Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients. RMD Open 8:e002255. https:\/\/doi.org\/10.1136\/rmdopen-2022-002255","journal-title":"RMD Open"},{"key":"6218_CR13","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1182\/blood.2023023723","volume":"144","author":"M Sirenko","year":"2024","unstructured":"Sirenko M, Bernard E, Creignou M et al (2024) Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes. Blood 144:1221\u20131229. https:\/\/doi.org\/10.1182\/blood.2023023723","journal-title":"Blood"},{"key":"6218_CR14","doi-asserted-by":"publisher","first-page":"101861","DOI":"10.1016\/j.berh.2023.101861","volume":"37","author":"M Heiblig","year":"2023","unstructured":"Heiblig M, Patel B, Jamilloux Y (2023) VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: a haematologist\u2019s point of view. Best Pract Res Clin Rheumatol 37:101861. https:\/\/doi.org\/10.1016\/j.berh.2023.101861","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"6218_CR15","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jaad.2022.01.042","volume":"89","author":"D Sterling","year":"2023","unstructured":"Sterling D, Duncan ME, Philippidou M et al (2023) VEXAS syndrome for the dermatologist. J Am Acad Dermatol 89:1209\u20131214. https:\/\/doi.org\/10.1016\/j.jaad.2022.01.042","journal-title":"J Am Acad Dermatol"},{"key":"6218_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000547236","volume":"17","author":"S Utz","year":"2025","unstructured":"Utz S, Lehmann M, Seyed Jafari SM et al (2025) Skin manifestations in VEXAS syndrome: specific clonal infiltrates versus non-specific reactive findings. Case Rep Dermatol 17:354\u2013361. https:\/\/doi.org\/10.1159\/000547236","journal-title":"Case Rep Dermatol"},{"key":"6218_CR17","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jamadermatol.2021.3344","volume":"157","author":"E Zakine","year":"2021","unstructured":"Zakine E, Schell B, Battistella M et al (2021) UBA1 variations in neutrophilic dermatosis skin lesions of patients with VEXAS syndrome. JAMA Dermatol 157:1349\u20131354. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3344","journal-title":"JAMA Dermatol"},{"key":"6218_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/ijd.16991","volume":"63","author":"D De","year":"2024","unstructured":"De D, Baskaran N, Shah S et al (2024) Cutaneous manifestations of VEXAS syndrome: multiple changing faces in the same patient. Int J Dermatol 63:517\u2013520. https:\/\/doi.org\/10.1111\/ijd.16991","journal-title":"Int J Dermatol"},{"key":"6218_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jamadermatol.2024.1657","volume":"160","author":"IJ Tan","year":"2024","unstructured":"Tan IJ, Ferrada MA, Ahmad S et al (2024) Skin manifestations of VEXAS syndrome and associated genotypes. JAMA Dermatol 160:822\u2013830. https:\/\/doi.org\/10.1001\/jamadermatol.2024.1657","journal-title":"JAMA Dermatol"},{"key":"6218_CR20","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1093\/rheumatology\/keaf293","volume":"64","author":"A Al-Hakim","year":"2025","unstructured":"Al-Hakim A, Goldberg S, Gaillard S et al (2025) Clinical features in VEXAS syndrome: a systematic review. Rheumatol (Oxf) 64:5217\u20135229. https:\/\/doi.org\/10.1093\/rheumatology\/keaf293","journal-title":"Rheumatology (Oxford)"},{"key":"6218_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.chest.2022.10.011","volume":"163","author":"R Borie","year":"2023","unstructured":"Borie R, Debray MP, Guedon AF et al (2023) Pleuropulmonary manifestations of VEXAS syndrome. Chest 163:575\u2013585. https:\/\/doi.org\/10.1016\/j.chest.2022.10.011","journal-title":"Chest"},{"key":"6218_CR22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00296-022-05266-2","volume":"43","author":"K Kouranloo","year":"2023","unstructured":"Kouranloo K, Ashley A, Zhao SS et al (2023) Pulmonary manifestations in VEXAS syndrome: a systematic review. Rheumatol Int 43:1023\u20131032. https:\/\/doi.org\/10.1007\/s00296-022-05266-2","journal-title":"Rheumatol Int"},{"key":"6218_CR23","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00296-023-05513-0","volume":"44","author":"K Kouranloo","year":"2023","unstructured":"Kouranloo K, Dey M, Almutawa J et al (2023) Clinical characteristics, disease trajectories and management of VEXAS syndrome: a systematic review. Rheumatol Int 44:1219\u20131232. https:\/\/doi.org\/10.1007\/s00296-023-05513-0","journal-title":"Rheumatol Int"},{"key":"6218_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.63032\/evgb1553","volume":"3","author":"M Puseljic","year":"2024","unstructured":"Puseljic M, Schmid J, Igrec J et al (2024) Pulmonary manifestations of VEXAS syndrome with acute interstitial pneumonia and diffuse alveolar haemorrhage: a case report and literature review. ARP Rheumatol 3:151\u2013156. https:\/\/doi.org\/10.63032\/evgb1553","journal-title":"ARP Rheumatol"},{"key":"6218_CR25","doi-asserted-by":"publisher","first-page":"e258140","DOI":"10.1136\/bcr-2023-258140","volume":"17","author":"T Knab","year":"2024","unstructured":"Knab T, Gaisl T, Steinack C et al (2024) Pulmonary manifestation of VEXAS syndrome. BMJ Case Rep 17:e258140. https:\/\/doi.org\/10.1136\/bcr-2023-258140","journal-title":"BMJ Case Rep"},{"key":"6218_CR26","doi-asserted-by":"publisher","first-page":"e719","DOI":"10.1016\/S2665-9913(25)00197-3","volume":"7","author":"A Kaul","year":"2025","unstructured":"Kaul A, Al-Hakim A, Lachmann H et al (2025) VEXAS syndrome and immune-mediated rheumatic diseases: overlaps in clinical features and mechanisms. Lancet Rheumatol 7:e719\u2013e733. https:\/\/doi.org\/10.1016\/S2665-9913(25)00197-3","journal-title":"Lancet Rheumatol"},{"key":"6218_CR27","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1182\/blood.2023022329","volume":"143","author":"Y Kusne","year":"2024","unstructured":"Kusne Y, Ghorbanzadeh A, Dulau-Florea A et al (2024) Venous and arterial thrombosis in patients with VEXAS syndrome. Blood 143:2190\u20132200. https:\/\/doi.org\/10.1182\/blood.2023022329","journal-title":"Blood"},{"key":"6218_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41584-025-01252-7","volume":"21","author":"F Bello","year":"2025","unstructured":"Bello F, Fagni F, Bagni G et al (2025) Arterial and venous thrombosis in systemic and monogenic vasculitis. Nat Rev Rheumatol 21:355\u2013369. https:\/\/doi.org\/10.1038\/s41584-025-01252-7","journal-title":"Nat Rev Rheumatol"},{"key":"6218_CR29","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1182\/blood.2024024161","volume":"143","author":"AF Gu\u00e9don","year":"2024","unstructured":"Gu\u00e9don AF (2024) VEXAS syndrome: from a vascular perspective. Blood 143:2118\u20132120. https:\/\/doi.org\/10.1182\/blood.2024024161","journal-title":"Blood"},{"key":"6218_CR30","doi-asserted-by":"publisher","first-page":"152796","DOI":"10.1016\/j.semarthrit.2025.152796","volume":"74","author":"D Montes","year":"2025","unstructured":"Montes D, Hanson AC, Langenfeld HE et al (2025) Developing efficient predictive models for the diagnosis of VEXAS syndrome. Semin Arthritis Rheum 74:152796. https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152796","journal-title":"Semin Arthritis Rheum"},{"key":"6218_CR31","doi-asserted-by":"publisher","first-page":"rkad012","DOI":"10.1093\/rap\/rkad012","volume":"7","author":"B Lucchino","year":"2022","unstructured":"Lucchino B, Delfino L, Patuzzo G et al (2022) SARS-CoV-2-induced venous thromboembolism in a patient with VEXAS syndrome. Rheumatol Adv Pract 7:rkad012. https:\/\/doi.org\/10.1093\/rap\/rkad012","journal-title":"Rheumatol Adv Pract"},{"key":"6218_CR32","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1055\/s-0043-1778105","volume":"50","author":"BE Fan","year":"2024","unstructured":"Fan BE, Sum CLL, Leung BPL et al (2024) VEXAS syndrome and thrombosis: findings of inflammation, hypercoagulability, and endothelial dysfunction. Semin Thromb Hemost 50:897\u2013901. https:\/\/doi.org\/10.1055\/s-0043-1778105","journal-title":"Semin Thromb Hemost"},{"key":"6218_CR33","doi-asserted-by":"publisher","first-page":"1377768","DOI":"10.3389\/fmed.2024.1377768","volume":"11","author":"M Zisapel","year":"2024","unstructured":"Zisapel M, Seyman E, Molad J et al (2024) Case report: cerebral sinus vein thrombosis in VEXAS syndrome. Front Med 11:1377768. https:\/\/doi.org\/10.3389\/fmed.2024.1377768","journal-title":"Front Med"},{"key":"6218_CR34","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s11239-021-02608-y","volume":"53","author":"TM Oo","year":"2022","unstructured":"Oo TM, Koay JTJ, Lee SF et al (2022) Thrombosis in VEXAS syndrome. J Thromb Thrombolysis 53:965\u2013970. https:\/\/doi.org\/10.1007\/s11239-021-02608-y","journal-title":"J Thromb Thrombolysis"},{"key":"6218_CR35","doi-asserted-by":"publisher","first-page":"103354","DOI":"10.1016\/j.eclinm.2025.103354","volume":"86","author":"F Efficace","year":"2025","unstructured":"Efficace F, Krepper D, Sparano F et al (2025) Exploring patient-reported outcomes and morbidity burden of patients with VEXAS syndrome: a scoping review. eClinicalMedicine 86:103354. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103354","journal-title":"eClinicalMedicine"},{"key":"6218_CR36","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1097\/RLU.0000000000006160","volume":"51","author":"H Goyal","year":"2026","unstructured":"Goyal H, Kumar SA, Abu Srinivasan A et al (2026) VEXAS syndrome presenting as erythema nodosum and pancytopenia: diagnostic utility of 18F-FDG PET\/CT in systemic inflammation. Clin Nucl Med 51:e470\u2013e471. https:\/\/doi.org\/10.1097\/RLU.0000000000006160","journal-title":"Clin Nucl Med"},{"key":"6218_CR37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ajh.27156","volume":"99","author":"MJ Koster","year":"2024","unstructured":"Koster MJ, Lasho TL, Olteanu H et al (2024) VEXAS syndrome: clinical, haematologic features and a practical approach to diagnosis and management. Am J Hematol 99:284\u2013299. https:\/\/doi.org\/10.1002\/ajh.27156","journal-title":"Am J Hematol"},{"key":"6218_CR38","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/blood.2025029081","volume":"147","author":"F Rodrigues","year":"2026","unstructured":"Rodrigues F, Hardouin G, El Hoss S et al (2026) VEXAS anaemia is a mosaic erythroblastopenia. Blood 147:1178\u20131190. https:\/\/doi.org\/10.1182\/blood.2025029081","journal-title":"Blood"},{"key":"6218_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/ajh.27169","volume":"99","author":"C Gurnari","year":"2024","unstructured":"Gurnari C, Pascale MR, Vitale A et al (2024) Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort. Am J Hematol 99:254\u2013262. https:\/\/doi.org\/10.1002\/ajh.27169","journal-title":"Am J Hematol"},{"key":"6218_CR40","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1182\/blood.2022018774","volume":"142","author":"F Gutierrez-Rodrigues","year":"2023","unstructured":"Gutierrez-Rodrigues F, Kusne Y, Fernandez J et al (2023) Spectrum of clonal haematopoiesis in VEXAS syndrome. Blood 142:244\u2013259. https:\/\/doi.org\/10.1182\/blood.2022018774","journal-title":"Blood"},{"key":"6218_CR41","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/rheumatology\/keae550","volume":"64","author":"MM Sullivan","year":"2025","unstructured":"Sullivan MM, Mead-Harvey C, Sartori-Valinotti JC et al (2025) Vasculitis associated with VEXAS syndrome. Rheumatol (Oxf) 64:3889\u20133894. https:\/\/doi.org\/10.1093\/rheumatology\/keae550","journal-title":"Rheumatology (Oxford)"},{"key":"6218_CR42","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1002\/ajh.27446","volume":"99","author":"H Oun","year":"2024","unstructured":"Oun H, Gordon W, Leach M et al (2024) Where haematology meets rheumatology\u2014VEXAS syndrome. Am J Hematol 99:2213\u20132214. https:\/\/doi.org\/10.1002\/ajh.27446","journal-title":"Am J Hematol"},{"key":"6218_CR43","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/ard-2024-225640","volume":"83","author":"J Hadjadj","year":"2024","unstructured":"Hadjadj J, Nguyen Y, Mouloudj D et al (2024) Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX. Ann Rheum Dis 83:1358\u20131367. https:\/\/doi.org\/10.1136\/ard-2024-225640","journal-title":"Ann Rheum Dis"},{"key":"6218_CR44","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1016\/j.mayocp.2021.06.006","volume":"96","author":"MJ Koster","year":"2021","unstructured":"Koster MJ, Kourelis T, Reichard KK et al (2021) Clinical heterogeneity of the VEXAS syndrome: a case series. Mayo Clin Proc 96:2653\u20132659. https:\/\/doi.org\/10.1016\/j.mayocp.2021.06.006","journal-title":"Mayo Clin Proc"},{"key":"6218_CR45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00296-025-05963-8","volume":"45","author":"G Rana","year":"2025","unstructured":"Rana G, Singh G, Mehta M et al (2025) From diagnostic uncertainty to targeted therapy: a case-based review of VEXAS syndrome. Rheumatol Int 45:217. https:\/\/doi.org\/10.1007\/s00296-025-05963-8","journal-title":"Rheumatol Int"},{"key":"6218_CR46","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/art.42471","volume":"75","author":"B Stiburkova","year":"2023","unstructured":"Stiburkova B, Pavelcova K, Belickova M et al (2023) Novel somatic UBA1 variant in a patient with VEXAS syndrome. Arthritis Rheumatol 75:1285\u20131290. https:\/\/doi.org\/10.1002\/art.42471","journal-title":"Arthritis Rheumatol"},{"key":"6218_CR47","doi-asserted-by":"publisher","first-page":"E28","DOI":"10.1002\/ajh.26786","volume":"98","author":"AA Mangaonkar","year":"2023","unstructured":"Mangaonkar AA, Langer KJ, Lasho TL et al (2023) Reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation in VEXAS syndrome: data from a prospective series of patients. Am J Hematol 98:E28\u2013E31. https:\/\/doi.org\/10.1002\/ajh.26786","journal-title":"Am J Hematol"},{"key":"6218_CR48","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1182\/bloodadvances.2023012478","volume":"8","author":"C Gurnari","year":"2024","unstructured":"Gurnari C, Koster L, Baaij L et al (2024) Allogeneic haematopoietic cell transplantation for VEXAS syndrome: results of a multicentre study of the EBMT. Blood Adv 8:1444\u20131448. https:\/\/doi.org\/10.1182\/bloodadvances.2023012478","journal-title":"Blood Adv"},{"key":"6218_CR49","doi-asserted-by":"publisher","first-page":"e828","DOI":"10.1097\/HS9.0000000000000828","volume":"7","author":"A Rabut","year":"2023","unstructured":"Rabut A, Jasserand L, Richard C et al (2023) Quantitative assessment of vacuolization of myeloid precursors in VEXAS syndrome. Hemasphere 7:e828. https:\/\/doi.org\/10.1097\/HS9.0000000000000828","journal-title":"Hemasphere"},{"key":"6218_CR50","doi-asserted-by":"publisher","first-page":"E60","DOI":"10.1002\/ajh.27192","volume":"99","author":"V Lacombe","year":"2024","unstructured":"Lacombe V, Genevieve F, Chabrun F (2024) Vacuoles in circulating immature myeloid cells in VEXAS syndrome and comparison with UBA1 wild-type patients. Am J Hematol 99:E60\u2013E62. https:\/\/doi.org\/10.1002\/ajh.27192","journal-title":"Am J Hematol"},{"key":"6218_CR51","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/bjh.19897","volume":"206","author":"C Gurnari","year":"2025","unstructured":"Gurnari C, Galossi E, Lumia E et al (2025) Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome. Br J Haematol 206:331\u2013336. https:\/\/doi.org\/10.1111\/bjh.19897","journal-title":"Br J Haematol"},{"key":"6218_CR52","doi-asserted-by":"publisher","first-page":"103352","DOI":"10.1016\/j.autrev.2023.103352","volume":"22","author":"SR Sangle","year":"2023","unstructured":"Sangle SR, Hughes CD, Barry L et al (2023) Relapsing polychondritis\u2014a single-centre study in the United Kingdom. Autoimmun Rev 22:103352. https:\/\/doi.org\/10.1016\/j.autrev.2023.103352","journal-title":"Autoimmun Rev"},{"key":"6218_CR53","doi-asserted-by":"publisher","first-page":"e251089","DOI":"10.1136\/bcr-2022-251089","volume":"15","author":"K Neupane","year":"2022","unstructured":"Neupane K, Jayarangaiah A, Zhang Y et al (2022) VEXAS syndrome with progression of MDS to MDS\/MPN overlap syndrome. BMJ Case Rep 15:e251089. https:\/\/doi.org\/10.1136\/bcr-2022-251089","journal-title":"BMJ Case Rep"},{"key":"6218_CR54","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/art.41992","volume":"74","author":"F Muratore","year":"2022","unstructured":"Muratore F, Marvisi C, Castrignan\u00f2 P et al (2022) VEXAS syndrome: a case series from a single-centre cohort of Italian patients with vasculitis. Arthritis Rheumatol 74:665\u2013670. https:\/\/doi.org\/10.1002\/art.41992","journal-title":"Arthritis Rheumatol"},{"key":"6218_CR55","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood.2022016642","volume":"140","author":"M Heiblig","year":"2022","unstructured":"Heiblig M, Ferrada MA, Koster MT et al (2022) Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicentre study. Blood 140:927\u2013931. https:\/\/doi.org\/10.1182\/blood.2022016642","journal-title":"Blood"},{"key":"6218_CR56","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1182\/blood.2024028133","volume":"146","author":"V Jachiet","year":"2025","unstructured":"Jachiet V, Kosmider O, Beydon M et al (2025) Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX. Blood 146:1450\u20131461. https:\/\/doi.org\/10.1182\/blood.2024028133","journal-title":"Blood"},{"key":"6218_CR57","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s10067-024-07160-7","volume":"43","author":"SB Ali","year":"2024","unstructured":"Ali SB, Gurnari C (2024) Allogeneic haematopoietic stem cell transplantation in VEXAS: a review of 33 patients. Clin Rheumatol 43:3565\u20133575. https:\/\/doi.org\/10.1007\/s10067-024-07160-7","journal-title":"Clin Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06218-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06218-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06218-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:17:25Z","timestamp":1784272645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06218-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":57,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["6218"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06218-w","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"18 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the reporting of this case was obtained from the Medical Ethics Committee of the General Hospital of Western Theater Command. The conduct of the work was consistent with local regulatory requirements and institutional guidelines, and written informed consent was obtained from the patient for publication.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and the accompanying images. A copy of the written consent is available for review.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No part of this work has been presented at a scientific meeting or published, in whole or in part, as a congress or conference abstract.","order":4,"name":"Ethics","label":"Prior presentation","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No part of this case-based review has been copied from, or published elsewhere in, any other work in whole or in part. The authors used generative artificial-intelligence tool solely to refine the language: Claude (Opus 4.8, Anthropic). These tools were not used to generate, analyse, or interpret clinical data.","order":5,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"191"}}